Arcellx sets IPO terms, looks to raise up to $140.3 m

 Arcellx Inc. ACLX, has set terms for its initial public offering, in which the Maryland-based biotechnology company, which is developing cancer treatments, looks to raise up to $140.25 million. The company said it is offering 8.25 million shares in the IPO, which is expected to price between $15 and $17 a share. With 33.54 million shares expected to be outstanding after the IPO, the expected pricing could value the company at up to $570.24 million. The stock is expected to list on the Nasdaq under the ticker symbol "ACLX." BofA Securities, SVB Leerink, Barclays and William Blair are the lead underwriters. The company recorded a net loss of $44.30 million on no revenue during the nine months ended Sept. 30, after a loss of $23.00 million on no revenue in the same period a year ago. Arcellx is looking to go public at a time of relative investor disdain for IPOs and biotechs, as the Renaissance IPO ETF IPO, +6.81% has plunged 37.2% over the past three months and the iShares Biotechnology ETF IBB, +1.96% has tumbled 19.8%, while the S&P 500 SPX, +0.95% has slipped 3.8%.

https://www.marketwatch.com/story/arcellx-sets-ipo-terms-looks-to-raise-up-to-1403-million-2022-01-31